Opinion|Videos|February 18, 2025
Real-World Observations With Pirtobrutinib and New Data From the BRUIN CLL-321 Trial at ASH 2024
Panelists discuss how real-world experience with pirtobrutinib generally aligns with the BRUIN study’s progression-free survival (PFS) data while sharing insights about common reasons for discontinuation and interpreting updated BRUIN CLL-321 trial results from ASH 2024 that may influence clinical decision-making regarding pirtobrutinib use in practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Have you observed similar median PFS duration with pirtobrutinib as reported out in the BRUIN study? What are your top clinical observations for patients having to discontinue or switch off pirtobrutinib?
- The BRUIN CLL-321 trial had data updates at ASH; could you sharekey highlights and your impressions so far and whether you anticipate this data to influence your use of pirtobrutinib in the real-life clinical setting?
Advertisement
Related to this article
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5